Noting an association between treatment with human immune globulin products and increased risk of thrombosis, the US Food and Drug Administration (FDA) has issued a boxed warning that cautions physicians and patients about that link.
The FDA, in a Safety Communication issued June 10, is requiring manufacturers of intravenous, subcutaneous, and intramuscular human immune globulin products to add information to the current boxed warning in the labels of these medications about the thrombosis risk and strategies to reduce such risk.
Mitka M. FDA: Thrombosis Risk With Immune Globulin Products. JAMA. 2013;310(3):247. doi:10.1001/jama.2013.15267
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: